Eliana Merle analyst UBS

Currently out of the existing stock ratings of Eliana Merle, 71 are a BUY (79.78%), 18 are a HOLD (20.22%).

Eliana Merle

Work Performance Price Targets & Ratings Chart

Analyst Eliana Merle works at UBS with a stock forecast success ratio of 44.49% fulfilled within 173.95 days on average.

Eliana Merle’s has documented 190 price targets and ratings displayed on 20 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on APLS, Apellis Pharmaceuticals at 08-May-2024.

Wall Street Analyst Eliana Merle

Analyst best performing recommendations are on ANAB (ANAPTYSBIO).
The best stock recommendation documented was for ANAB (ANAPTYSBIO) at 11/7/2019. The price target of $28 was fulfilled within 1 day with a profit of $8.16 (22.57%) receiving and performance score of 225.66.

Average potential price target upside

APLS Apellis Pharmaceuticals ARVN Arvinas BBIO BridgeBio Pharma BNTX BioNTech SE CBAY Cymabay Therapeu DRRX Durect KDMN Kadmon Holdings ZNTL Zentalis Pharmaceuticals Llc ANAB AnaptysBio BMRN Biomarin Pharmaceutical GLPG Galapagos NV ADR GOSS Gossamer Bio IONS Ionis Pharmaceuticals MRNA Moderna QURE Uniqure NV ISEE IVERIC bio PRQR ProQR Therapeutics BV AKRO Akero Therapeutics ETNB 89bio KOD Kodiak Sciences

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

60

$18.69 (45.24%)

67

10 days ago

20/23 (86.96%)

$17.7 (41.84%)

216

Buy

92

$50.69 (122.71%)

92

10 days ago

3/16 (18.75%)

$49.7 (117.49%)

108

Buy

85

$43.69 (105.76%)

85

10 days ago

10/14 (71.43%)

$42.7 (100.95%)

230

Buy

85

$43.69 (105.76%)

89

10 days ago

5/7 (71.43%)

$42.7 (100.95%)

391

Hold

52

$10.69 (25.88%)

60

19 days ago

3/5 (60%)

$2.14 (4.29%)

73

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Eliana Merle is most bullish on?

Potential upside of $43.69 has been obtained for APLS (APELLIS PHARMACEUTICALS)

Which stock is Eliana Merle is most reserved on?

Potential downside of $0.02 has been obtained for CBAY (CYMABAY THERAPEU)

What Year was the first public recommendation made by Eliana Merle?

On 2016

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?